Diagnosis and treatment of acute myocardial infarction in tertiary and secondary care hospitals in Estonia

Abstract

Aim: To compare validity of AMI diagnosis and treatment of AMI patients between tertiary and secondary care hospitals in Estonia. Methods: Two tertiary and seven secondary care hospitals responsible for the treatment of most AMI patients in Estonia were included in the analysis. A random sample of 520 patients admitted to these hospitals with AMI in 2001 was taken from the Estonian Health Insurance Fund database. Medical records were reviewed by trained experts using a standardized data collection form. Results: Forty cases were excluded due to selection errors by the Health Insurance Fund. Of the remaining cases, a diagnosis of AMI was confirmed in 93.3% of cases in tertiary care hospitals and in 83.5% of cases in secondary care hospitals (p<0.001). A total of 210 cases from tertiary and 213 cases from secondary care hospitals with confirmed AMI diagnoses were included in subsequent analysis. Utilization of β-blockers, aspirin, and reperfusion therapy was similar in both types of hospitals. In tertiary care hospitals, ACE inhibitors and statins were more frequently used during hospital stay and recommended at discharge compared with secondary care hospitals. In-hospital mortality was similar in both types of hospitals both before and after adjustment. Conclusions: Tertiary care physicians adhered more strictly to the current definition and guidelines for the management of AMI than did secondary care physicians. However, there is still a need for further improvement in both hospital settings according to international guidelines.

Keywords

acute myocardial infarction diagnosis hospital type treatment

Get full access to this article

View all access options for this article.

References

Ministry of Social Affairs of Estonia. Social sector in figures 2002. Tallinn: 2002.

Sans S. , Kesteloot H. , Kromhaut D. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997;18:1231—48.

Capewell S. , Morrison CE , McMurray JJ Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999 ;81:380—6.

Heidenreich PA , McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975—1995. Am J Med 2001;110:165—74.

Leinsalu M. Time trends in cause-specific mortality in Estonia from 1965 to 1989. Int J Epidemiol 1995;24: 106—13.

Fox KA , Goodman SG , Klein W. , Brieger D. , Steg PG , Dabbous O. , Avezum A. Management of acute coronary syndromes: Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23:1177—89.

Hasdai D. , Behar S. , Wallentin L. , Danchin N. , Gitt AK , Boersma E. , et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey) . Eur Heart J 2002; 23:1190—201.

Gottwik M. , Zahn R. , Schiele R. , Schneider S. , Gitt AK , Fraunberger L. , et al. Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology. Eur Heart J 2001;22:1784—801.

Jollis JG , DeLong ER , Peterson ED , Muhlbaier LH , Fortin DF , Califf RM , Mark DB Outcome of acute myocardial infarction according to the speciality of the admitting physician. N Engl J Med 1996;335:1880—7.

10.

The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined — a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction . Eur Heart J 2000;21:1502—13.

11.

Task Force of the European Society of Cardiology. Acute myocardial infarction: Pre-hospital and in-hospital management. Eur Heart J 1996;17:43—63.

12.

Committee on Management of Acute Myocardial Infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction) . J Am Coll Cardiol 1999;34:890—911.

13.

Task Force of European Society of Cardiology. Bertrand ME , Simoons ML , Fox K. , Wallentin LC , Hamm CW , McFadden E. , et al. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation. Eur Heart J 2000;21: 1406—32.

14.

World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th revision. Geneva: WHO, 1992.

15.

Acute Coronary Syndromes Writing Committee. A report of the American College of Cardiology Task Force on Clinical Data Standards. American College of Cardiology key elements and data definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. J Am Coll Cardiol 2001;38:2114—30.

16.

Stata user's guide, College Station, TX : Stata Press, 1997.

17.

Abramson JH , Gahlinger PM Computer Programs for Epidemiologic Analyses: PEPI v. 4.0 [available at: http://www.sagebrushpress.com/pepibook.html;www.brixtonhealth.com ].

18.

Hasdai D. , Behar S. , Boyko V. , Danchin N. , Bassand JP , Battler A. Cardiac biomarkers and acute coronary syndromes: The Euro Heart Survey of Acute Coronary Syndromes Experience. Eur Heart J 2003;24:1189—94.

19.

Van Berkel TFM , Boersma H. , De Barque D. , Deckers JW , Wood D. , on behalf of the EUROASPIRE Study Group. Registration and management of smoking behavior in patients with coronary heart disease. Eur Heart J 1999;20:1630—7.

20.

Harnick DJ , Cohen JL , Schechter CB , Fuster V. , Smith DA Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol 1998;81:1416—20.

21.

Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients . Lancet 1994;343:311—22.

22.

First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57—66.

23.

Latini R. , Maggioni AP , Flather M. , Sleight P. , Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995;92:3132—7.